Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

9480	Companies
185524	Keywords
117913	Articles
99371	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
BRIEF

published on 11/21/2024 at 14:35, 1 year ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform
BRIEF

published on 11/12/2024 at 15:05, 1 year ago

Xenetic Biosciences annonce des résultats précliniques positifs pour la thérapie par DNase I et anti-CTLA-4 dans le cancer colorectal

Immunothérapie Biosciences Xénétiques Données Précliniques Thérapie À L'ADNase I Carcinome Colorectal
BRIEF

published on 11/12/2024 at 15:05, 1 year ago

Xenetic Biosciences Reports Positive Preclinical Results for DNase I and Anti-CTLA-4 Therapy in Colorectal Cancer

Xenetic Biosciences Preclinical Data Immunotherapy DNase I Therapy Colorectal Carcinoma
PRESS RELEASE

published on 11/12/2024 at 15:00, 1 year ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors

DNase I SITC 2024 CTLA-4 Antibody Antitumor Immunity Immunological Memory

Accesswire

Published on 12/05/2025 at 18:45, 8 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 33 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 53 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 1 hour 38 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 53 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:26, 27 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 38 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 1 hour 1 minute ago

Issue of Equity
Published on 12/05/2025 at 17:46, 1 hour 7 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 53 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance

Les Echos

Published on 12/05/2025 at 17:18, 1 hour 35 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 1 hour 35 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 3 hours 42 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 3 hours 42 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 55 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE